Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Anesthesiology, Weill Cornell Medical College, New York, New York.
Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Anesthesiology. 2024 Dec 1;141(6):1065-1074. doi: 10.1097/ALN.0000000000005224.
The efficacy of serratus anterior plane block for treatment of pain after minimally invasive thoracic surgery remains unclear. This trial assesses the impact of serratus anterior plane block on postoperative opioid consumption and on measures of early recovery after thoracoscopic lung resection.
Patients undergoing minimally invasive anatomic lung resection at a single center were randomized to undergo serratus anterior plane block with 40 ml injectate containing bupivacaine 0.25%, clonidine 100 μg, and dexamethasone 4 mg (serratus anterior plane block group) or sham block with 40 ml normal saline (placebo group) at the conclusion of surgery. The primary outcome was cumulative intravenous morphine equivalents during the first 24 h postoperatively. Secondary outcomes were intravenous morphine equivalents, pain scores at rest and with cough, inspiratory volume on incentive spirometry, incidence of nausea or vomiting during the first 48 h postoperatively, Quality of Recovery-15 score on postoperative day 7, and length of stay.
Using the protocol-specified intention-to-treat analysis, the median (interquartile range) intravenous morphine equivalents was 10.6 (5.0 to 27.1) mg in serratus anterior plane block patients (n = 46) versus 18.8 (9.9 to 29.6) mg in placebo patients (n = 46; 32% reduction; ratio, 0.68 [95% CI, 0.44 to 1.06]; P = 0.085). Of the secondary outcomes, only the composite pain with cough scores differed significantly in the serratus anterior plane block group by a coefficient of -0.41 (95% CI, -0.81 to -0.01; P = 0.044). A sensitivity as-treated analysis reported median (interquartile range) intravenous morphine equivalents of 10.0 (5.0 to 27.2) mg in serratus anterior plane block patients (n = 44) versus 19.9 (10.4 to 29.0) mg in placebo patients (n = 48; 36% reduction; ratio, 0.64 [95% CI, 0.41 to 1.00]; P = 0.048).
The protocol-specified intention-to-treat analysis demonstrated that serratus anterior plane block did not result in a significant reduction in opioid consumption when added to a multimodal analgesic regimen after thoracoscopic anatomic lung resection. The sensitivity as-treated analysis showed a significant and modest clinical reduction in the primary outcome that warrants further investigation.
胸壁神经阻滞(SAB)在微创胸科手术后镇痛的疗效尚不清楚。本试验评估了 SAB 对胸腔镜肺切除术后阿片类药物消耗和早期恢复的影响。
在一家中心接受微创解剖性肺切除术的患者被随机分为两组:SAB 组在手术结束时接受含有布比卡因 0.25%、可乐定 100μg 和地塞米松 4mg 的 40ml 塞来昔布(SAB 组)或假阻滞(生理盐水 40ml)(安慰剂组)。主要结局是术后 24 小时内静脉注射吗啡等效物的累积量。次要结局包括静脉注射吗啡等效物、静息和咳嗽时的疼痛评分、激励肺活量计的吸气量、术后 48 小时内恶心或呕吐的发生率、术后第 7 天的恢复质量-15 评分和住院时间。
采用方案规定的意向治疗分析,SAB 组患者(n=46)的静脉注射吗啡等效物中位数(四分位距)为 10.6(5.0 至 27.1)mg,安慰剂组患者(n=46)为 18.8(9.9 至 29.6)mg(32%减少;比值,0.68[95%CI,0.44 至 1.06];P=0.085)。在次要结局中,只有复合咳嗽疼痛评分在 SAB 组中差异有统计学意义,差值为-0.41(95%CI,-0.81 至-0.01;P=0.044)。基于治疗的敏感性分析报告,SAB 组患者(n=44)的静脉注射吗啡等效物中位数(四分位距)为 10.0(5.0 至 27.2)mg,安慰剂组患者(n=48)为 19.9(10.4 至 29.0)mg(36%减少;比值,0.64[95%CI,0.41 至 1.00];P=0.048)。
方案规定的意向治疗分析表明,在胸腔镜解剖性肺切除术后加入多模式镇痛方案时,SAB 并未导致阿片类药物消耗显著减少。基于治疗的敏感性分析显示,主要结局有显著和适度的临床改善,值得进一步研究。